Autoimmunity and malaria: what are they doing together?
A common feature of autoimmunity is the presence of autoantibodies (AAb). Two types of AAb have been described: the 'pathogenic' AAb, associated with autoimmune diseases (AID), and the so-called 'natural' AAb. The latter are present in all normal individuals and have been postulated to play a major role as a first defensive barrier of the organism. Both the 'pathogenic' and the 'natural' AAb can be detected at higher frequencies among individuals exposed to viral, bacterial and parasitic infections. The malaria associated AAb do not seem to result from a generalised polyclonal B-cell activation (PBA), have specificities that may differ according to the degree of clinical immunity and do not seem to be pathogenic. Malaria may offer a protective effect against AID, by diminishing its severity or by either preventing or retarding its expression. AAb could also participate in the immune protection against malaria, and this could happen in several ways: (i) AAb directed to modified Ag expressed on the red blood cell (RBC) membrane during parasitisation and (ii) AAb reactive with crypto- or neo-Ag revealed on both normal and infected RBC membranes, by destroying infected, and also normal, erythrocytes; (iii) anti-idiotype AAb specific of the binding site of anti-merozoite Ab, which would mimic the parasite ligand for the RBC receptor, by competing with parasites and blocking RBC invasion; (iv) AAb cross-reactive with parasite material - such as nuclear or cytoskeleton Ag - having a direct parasiticide activity; (v) the natural AAb network, through its 'anti-bacterial first defense barrier'; and finally (vi) anti-phospholipid (PL) AAb, by neutralizing the pathogenic properties of parasite-derived PL. Finally, in view of currently available knowledge, it is concluded that, since AAb are not always pathogenic, the price for an 'autoimmunity-mediated' protection in malaria would not necessarily be immunopathology and clinical autoimmunity, and a protective role of AAb could be exerted with no danger to the host.
Daniel-Ribeiro
C T
CT
Department of Immunology, Instituto Oswaldo Cruz-Fiocruz, Av. Brasil 4365, CEP 21.045-900 RJ, Rio de Janeiro, Brazil. ribeiro@ioc.fiocruz.br
Zanini
G
G
D000818:Animals; D000937:Antigen-Antibody Reactions; D000953:Antigens, Protozoan / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology / Q000494:pharmacology; D001327:Autoimmune Diseases / Q000276:immunology*; D001665:Binding Sites / Q000276:immunology; D002467:Cell Nucleus / Q000276:immunology; D004912:Erythrocytes / Q000276:immunology; D006801:Humans; D008288:Malaria / Q000276:immunology* / Q000517:prevention & control; D010743:Phospholipids / Q000276:immunology; D010963:Plasmodium falciparum / Q000276:immunology
D000953:Antigens, Protozoan; D001323:Autoantibodies; D010743:Phospholipids